Cases from the Community: Investigators Discuss the Optimal Management of Chronic Lymphocytic Leukemia

A CME Symposium Held Adjunct with the 2026 ASCO^® Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

Meeting Room
Continental Room B (Lobby Level)

No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Faculty

John N Allan

Weill Cornell Medicine New York, New York

Associate Professor of Clinical Medicine

Faculty

Bita Fakhri

MD, MPH

Stanford University School of Medicine, Stanford, California

Assistant Professor of Medicine (Hematology)

Faculty

Mazyar Shadman

MD, MPH

Fred Hutchinson Cancer Center and University of Washington Seattle, Washington

Professor Innovators Network Endowed Chair Deputy Chief Medical Officer Medical Director, Cellular Immunotherapy Professor, Clinical Research Division

Moderator

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Additional faculty to be announced.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.

Not an official event of the 2026 ASCO^® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO^®, Association for Clinical Oncology, or Conquer Cancer^®, the ASCO Foundation.

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

MODULE 1: Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Clinical, biological and practical factors in the selection of front-line therapy for patients with CLL requiring treatment
Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current up-front decision-making
Pharmacological similarities and differences between covalent and noncovalent BTK inhibitors
Emerging positive findings from the Phase III BRUIN CLL-314 study of pirtobrutinib versus ibrutinib for patients with treatment-naïve or previously treated, BTK inhibitor-naïve CLL
Emerging data documenting an efficacy advantage with pirtobrutinib versus bendamustine/rituximab for patients with treatment-naïve CLL without del(17p) in the Phase III BRUIN CLL-313 trial
Potential clinical role of pirtobrutinib in therapy for newly diagnosed CLL

MODULE 2: Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL

Long-term data with up-front venetoclax/obinutuzumab for CLL
Mechanistic rationale for combining BTK inhibitors and venetoclax with and without anti-CD20 antibodies for CLL
Published findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
Recent FDA approval of fixed-duration acalabrutinib and venetoclax for patients with treatment-naïve CLL; integration into current clinical algorithms
Early data with zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax or sonrotoclax, with or without an anti-CD20 antibody, for treatment-naïve CLL
Anticipated read-out and potential clinical implications of the Phase III CLL17 trial evaluating fixed-duration versus continuous targeted treatment for previously untreated CLL

MODULE 3: Optimal Management of Adverse Events (AEs) Associated with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations

Relevant patient comorbidities, such as hypertension, preexisting cardiac arrhythmias, chronic kidney disease and chronic migraines, and concomitant medications that might influence the choice of therapy for CLL
Spectrum, frequency and severity of cardiovascular AEs with covalent and noncovalent BTK inhibitors; optimal monitoring and management protocols
Incidence and management of noncardiovascular AEs associated with covalent and noncovalent BTK inhibitors
Frequency of tumor lysis syndrome and other common AEs reported with venetoclax for CLL, such as cytopenias, infections, gastrointestinal disorders; monitoring, prophylaxis and management protocols
Incidence, severity and management of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies

MODULE 4: Selection and Sequencing of Therapy for R/R CLL

Clinical and biological factors guiding decision-making for patients with R/R CLL; impact of the evolving up-front CLL treatment paradigm on the management of R/R disease
Long-term follow-up from Phase III trials evaluating covalent BTK inhibitors and Bcl-2 inhibitors for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy
Published findings from key trials, such as BRUIN and BRUIN CLL-32, supporting the use of pirtobrutinib for patients with R/R CLL
Available and emerging efficacy and safety data with and ongoing evaluation of other noncovalent BTK inhibitors, such as nemtabrutinib and rocbrutinib, for R/R and treatment-naïve CLL
Similarities and differences between sonrotoclax and venetoclax; early data with sonrotoclax in combination with an anti-CD20 antibody for R/R and treatment-naïve CLL and ongoing Phase III evaluation for R/R disease

MODULE 5: Other Novel Strategies for CLL

Biological rationale for the evaluation of CAR T-cell therapy in CLL
Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
Optimal approaches to bridging therapy and other practical and safety considerations with CAR T-cell therapy
Early antitumor-activity and safety data with bispecific antibodies for R/R CLL and CLL with Richter’s syndrome
Mechanistic similarities and differences between BTK degraders and BTK inhibitors; implications for efficacy in patients with BTK resistance mutations
Updated safety and efficacy of the BTK degrader BGB-16673 for patients with heavily pretreated CLL in the Phase I CaDAnCe-101 study; FDA fast track designation and potential clinical role

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
Evaluate available and emerging Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and relapsed/refractory CLL, and identify patients appropriate for treatment with these agents.
Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented and emerging data with and the current and potential role of this strategy for patients with newly diagnosed and relapsed/refractory CLL.
Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom treatment with this novel therapeutic strategy would be appropriate.
Recall available data with novel agents and combination strategies currently under investigation for CLL and, as applicable, discuss clinical trial participation with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Allan — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: Adaptive Biotechnologies Corporation, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Shadman — Advisory Committees and Consulting Agreements: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, MorphoSys, Nurix Therapeutics Inc, Pfizer Inc, Pierre Fabre; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Merck, MorphoSys, Nurix Therapeutics Inc, Sana Biotechnology; Stock OPTIONS — Private Companies: Koi Biotherapeutics Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb (spouse employment).

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

You have successfully registered

See you on Friday, May 29

Format:

Chicago, IL

Date & Time:

Friday, May 29 6:30 PM — 8:30 PM CT

This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel*, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.

No fee is charged to attend the session virtually.

NOTICE:
Registration for this event is independent of registration for the 2026 ASCO Annual Meeting.

Webinar

In-Person

I am a:(Required)

Clinician / healthcare professional

Other / industry professional

Registration

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Clinical background:

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

National Provider Identifier (NPI) Number

How did you learn about this symposium:(Required)

Industry registration:

Professional designation(Required)

Institution/Organization

To register for this event, please log in.

Don’t have an account?

Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

Accreditation types: 2.25 ABIM MOC, CME

Expires: January 2027

To play this presentation please log in.

Don't have an account?

Symposium Video Proceedings

1h 55min

Faculty

Matthew S Davids

MD, MMSc

Harvard Medical School, Boston, Massachusetts

Associate Professor of Medicine

Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

Leader, Lymphoma Program

Dana-Farber Cancer Institute, Boston, Massachusetts

Director of Clinical Research, Division of Lymphoma

Faculty

Professor Constantine Tam

MBBS, MD

Alfred Health, Melbourne, Australia

Head of Lymphoma Service

Monash University, Melbourne, Australia

Professor of Haematology

Faculty

Bita Fakhri

MD, MPH

Stanford University School of Medicine, Stanford, California

Assistant Professor of Medicine (Hematology)

Faculty

Jennifer Woyach

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Professor, Division of Hematology, Department of Internal Medicine

TARGET AUDIENCE
This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

LEARNING OBJECTIVES

Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and preferences for time-limited or continuous treatment.
Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
Evaluate available and emerging Phase III data demonstrating the efficacy of covalent and noncovalent BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL, and counsel patients regarding the risks and benefits of this novel treatment strategy.
Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with CLL.
Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for relapsed/refractory CLL, and use this information to identify patients appropriate for treatment with these agents.
Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom treatment with this novel therapeutic strategy would be appropriate.
Implement a plan of care to recognize and manage side effects and toxicities associated with available systemic therapies commonly employed in the treatment of CLL.
Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL, and as applicable, refer eligible patients for clinical trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHCLL25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, MEI Pharma Inc, Novartis; Nonrelevant Financial Relationships: UpToDate.

Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.

Professor Constantine Tam, MBBS, MD
Head of Lymphoma Service
Alfred Health
Professor of Haematology
Monash University
Melbourne, Australia

No relevant financial relationships to disclose.

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Newave, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.

Release date: January 2026
Expiration date: January 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Davids

Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 2024;144(18):1924-35. Abstract

Brown JR et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392(8):748-62. Abstract

Burger JA et al. Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood 2025;146(18):2168-76. Abstract

Davids MS et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naïve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol 2025;43(7):788-99. Abstract

Davids MS et al. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials. Blood Adv 2024;8(13):3345-59. Abstract

Davids MS et al. Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States. Blood Neoplasia 2024;2(1):100047. Abstract

Fürstenau M et al. The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: Final analysis from the phase 3 GAIA/CLL13 trial. EHA 2025;Abstract S191.

Jurczak W et al. Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study examining a non-covalent BTG inhibitor in untreated patients. ASH 2025;Abstract LBA-3.

Liu J et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood 2024;143(18):1825-36. Abstract

Shadman M et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA. J Clin Oncol 2025;43(7):780-7. Abstract

Shadman M et al. CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL. ASCO 2024;Abstract TPS7087.

Sharman JP et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 2025;146(11):1276-85. Abstract

Soumerai JD et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101. Blood 2024;144(1_Suppl):1012. Abstract

Tam CS et al. Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: Analysis across clinical studies. Blood Adv 2025;[Online ahead of print]. Abstract

Woyach J et al. Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized study III study comparing a non-covalent and covalent BTK inhibitor. ASH 2025;Abstract 87.

Prof Tam

Brown JR et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392(8):748-62. Abstract

Munir T et al. Practical management of cardiovascular adverse events with BTKi treatment in patients with chronic lymphocytic leukemia: A consensus report by hematologists and cardiologists. Acta Haematol 2025;[Online ahead of print]. Abstract

Shadman M et al. Zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma with and without del(17p)/ TP53 mutation: SEQUOIA arm D results. J Clin Oncol 2025;43(21):2409-17. Abstract

Timofeeva N et al. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: Synergy in practice. Blood Neoplasia 2024;1(3):100034. Abstract

Dr Woyach

Davids M et al. Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (REVENG) in patients with recurrent chronic lymphocytic leukemia (CLL). EHA 2025;Abstract PF575.

Jain N et al. Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax. Clin Cancer Res 2024;30(3):498-505. Abstract

Sharman JP et al. Phase III trial of pirtobrutinib versus idelalisib/rituximab or bendamustine/rituximab in covalent bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol 2025;43(22):2538-49. Abstract

Sharman JP et al. BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (idelar) or bendamustine plus rituximab (br) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2024;Abstract 886.

Woyach J et al. Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor. ASH 2025;Abstract 683.

Woyach JA et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-hodgkin lymphoma. Cancer Discov 2024;14(1):66-75. Abstract

Dr Fakhri

Ahn I et al. Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB- 16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study. ASH 2025;Abstract 85.

Omer Z et al. Bexobrutideg (NX-958), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial. ASH 2025;Abstract 86.

Winter AM et al. Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). ASCO 2024;Abstract 7010.

Woyach J et al. Updates of R/R CLL with prior exposure to Bruton’s tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the phase 1 trial of LP-168 (rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor. ASH 2025;Abstract 87.

Zhou K et al. Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis). ASH 2025;Abstract 88.

Understanding the Current Paradigm and New Approaches in the Care of Patients with Chronic Lymphocytic Leukemia

Accreditation types: 1.75 NCPD

To play this presentation please log in.

Don't have an account?

Nursing Symposium Video Proceedings

1h 31min

Faculty

Jacqueline Broadway-Duren

PhD, DNP, APRN, FNP-BC

The University of Texas MD Anderson Cancer Center Houston, Texas

Family Nurse Practitioner Department of Leukemia

Faculty

Bita Fakhri

MD, MPH

Stanford University School of Medicine Stanford, California

Assistant Professor of Medicine (Hematology)

Faculty

Corinne Hoffman

MS, APRN-CNP, AOCNP

The Ohio State University Wexner Medical Center Columbus, Ohio

Nurse Practitioner, Hematology The James Comprehensive Cancer Center

Faculty

Jeff Sharman

Sarah Cannon Research Institute at Willamette Valley Cancer Center Eugene, Oregon

Medical Director of Hematology Research

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with chronic lymphocytic leukemia.

LEARNING OBJECTIVES

Individualize the selection of systemic therapy for newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
Evaluate available Phase III data demonstrating the efficacy and safety of Bruton tyrosine kinase (BTK) inhibition as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options.
Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL, and counsel patients regarding the risks and benefits of this novel therapeutic strategy.
Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory CLL to provide education regarding appropriate treatment considerations.
Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors for patients with CLL, and identify candidates for whom treatment with these agents would be appropriate.
Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/CLL/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
Audio Program: This NCPD activity consists of an audio component. To receive credit, the participant should review the NCPD information, listen to the MP3s, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/CLL/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONS2025/CLL/Video.

Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/CLL/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONS2025/CLL.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC
Family Nurse Practitioner
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committees: AbbVie Inc, BeiGene Ltd.

Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeiGene Ltd, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Speakers Bureaus: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.

Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner, Hematology
The James Comprehensive Cancer Center
The Ohio State University Wexner Medical Center
Columbus, Ohio

No relevant financial relationships to disclose.

Jeff Sharman, MD
Medical Director of Hematology Research
Sarah Cannon Research Institute at
Willamette Valley Cancer Center
Eugene, Oregon

Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Sharman

Module 1: Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL

Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract

Dr Broadway-Duren

Module 1

Cool A et al. BTK inhibitors: Past, present, and future. Trends Pharmacol Sci 2024;45(8):691-707. Abstract

Module 4: CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL

Jain MD et al. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 2023;141(20):2430-42. Abstract

Dr Fakhri

Module 2: Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL

Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.

Brown JR et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. ASH 2024;Abstract 1009.

Burger JA et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34(3):787-98. Abstract

Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432-43. Abstract

Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: Scientific rationale and clinical results. Blood Cancer J 2021;11(4):79. Abstract

Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract

Module 3: Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL

Robak T et al. The role of bruton’s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel). 2022 Feb 2;14(3):771. Abstract

Sharman JP et al. BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2024;Abstract 886.

Woyach JA et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023;Abstract 325.

for-nurses